|
Categories |
|
Women's Health |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Major Milestones: Female Sexual Dysfunction 11-Aug-2005
Synopsis of the FSD market, covering disease pathology, epidemiology, treatment approaches and pipeline opportunities, including an assessment of how Intrinsa's failure to get FDA approval will impact market development.
------------------------------------------------------------------------------------------------------------------------- |
2- Commercial Insight: Osteoporosis and HRT - Novel
Osteoporosis Drugs Counter Generic Threat 15-Oct-2004
Analysis of environmental issues
affecting osteoporosis and HRT in major pharmaceutical markets with
country specific market forecast based on IMS sales data. Includes
forecast analysis and case studies of key brands, classes and
players.
------------------------------------------------------------------------------------------------------------------------- |
3- Pipeline Insight: Endometriosis - Growing the Patient
Population is Key to Unlocking the Market's Commercial Potential
29-Jul-2004
In-depth analysis of the endometriosis pipeline
covering key products in development.
------------------------------------------------------------------------------------------------------------------------- |
4- Urinary Incontinence: Market Update - Growing Market
Brings Opportunities for New Drugs 23-Dec-2003
An update of "CNS Disorders in
Women Urinary Incontinence" (DMHC1754) - latest developments in the
UI pipeline, analyzing the effects the drugs in late-stage
development will have on the current market leaders.
-------------------------------------------------------------------------------------------------------------------------
|
5- Stakeholder Insight: Osteoporosis - Poor Disease
Awareness and Patient Identification Hinder Market
Growth 19-Nov-2003
Detailed
analysis of prescribing trends in osteoporosis by disease severity,
physician specialty and country, and identifies stakeholder
relationships and key unmet needs in screening, diagnosis and
treatment.
-------------------------------------------------------------------------------------------------------------------------
|
6- The Women's Health Outlook to 2008: Market and
pipeline analysis of major female disorders 1-Nov-2003
This
report examines the four major female disorders: hormone replacement
therapy, osteoporosis, hormonal contraception and female sexual
dysfunction.
-------------------------------------------------------------------------------------------------------------------------
|
7- Commercial Insight: Osteoporosis & HRT - HRT is
down for the count, but can osteoporosis players pick up the
pieces?
4-Sep-2003
Analysis of the key drug classes used to treat and
prevent osteoporosis, with a discussion of best practice strategies
in the commercialization of drugs in the osteoporosis market, across
multiple stages of the product
lifecycle.
-------------------------------------------------------------------------------------------------------------------------
|
8- Pipeline Insight: Hormone Replacement Therapy - Wyeth
positions to strike back? 17-Jun-2003
Analysis of pipeline R&D products in development
for the treatment of HRT.
-------------------------------------------------------------------------------------------------------------------------
|
9- Hormonal Contraception: Market Update - Surviving the
Generic Threat
25-Mar-2003
Analysis of market response to
the patent expiry of Ortho Tri-Cyclen.
-------------------------------------------------------------------------------------------------------------------------
|
10- Strategic Perspectives: Hormone Replacement Therapy -
Women’s Health Initiative Drives Long-term Shift Towards Short-term
Treatment
5-Mar-2003
Insight into Stakeholder perception of the
suspension of the WHI estrogen/progestin trial.
-------------------------------------------------------------------------------------------------------------------------
|
| |
| |
| |
